TrovaGene Inc (NASDAQ:TROV) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors there is some hope when looking at TROV given that, according to its RSI reading of 24.68, it is now in oversold territory. TrovaGene Inc (NASDAQ:TROV) stock performance was 8.73% in last session and finished the day at $4.11. Traded volume was 130,754.00million shares in the last session and the average volume of the stock remained 66.64K shares. The beta of the stock remained -0.90. TrovaGene Inc (NASDAQ:TROV) insider ownership is 14.93%.
Investment analysts at Bank of America assumed coverage on shares of Vital Therapies Inc (NYSE:VTL) in a note issued to investors on Monday, American Banking News.com reports. The firm set a “buy” rating on the stock. Vital Therapies Inc (NASDAQ:VTL) rose 5.83 percent to $12.70 Monday on volume of 51.11K shares. Vital Therapies Inc (NASDAQ:VTL) has a market capitalization of $268.22million.
RXi Pharmaceuticals Corp. (NASDAQ:RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, announced that it received the notice of allowance from the U.S. Patent and Trademark Office on its novel, self-delivering RNAi platform (sd rxRNA). The patent, titled “Reduced Size Self-Delivering RNAi Compounds”, broadly covers both the composition and methods of use of RXi’s self-delivering platform technology. The patent, once issued, will be scheduled to expire in 2029. RXi Pharmaceuticals Corp (NASDAQ:RXII)’s stock on 02 June, 2014 reported a increase of 5.95% to the closing price of $2.85. Its fifty two weeks range is $2.55 -$6.84. The total market capitalization recorded $39.98million. The overall volume in the last trading session was 140,783.00million shares. In its share capital, RXII has 14.01million outstanding shares.
Applied Genetic Technologies Corp (NASDAQ:AGTC) released its earnings data on Wednesday. The company reported ($25.45) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.37) by $25.08, American Banking and Market News reports. The company had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.15 million. On Monday, shares of Applied Genetic Technologies Corp (NASDAQ:AGTC) advanced 44.09% to close the day at $19.74. Company return on investment (ROI) is 10.60% and its monthly performance is recorded as 56.92%.
IGI Laboratories Inc. (NYSEMKT:IG), a Buena generic topical pharmaceutical company, has appointed Damian Finio to its board. Finio will also serve as chairman of the company’s Audit Committee. He is president of Mountain Run Advisors L.L.C., a niche financial consulting firm and had been vice president and chief financial officer of West-Ward Pharmaceuticals. IGI Laboratories, Inc. (NYSEMKT:IG) stock performance was 7.40% in last session and finished the day at $5.66. Traded volume was 326,487.00million shares in the last session and the average volume of the stock remained 304.31K shares. The beta of the stock remained 0.57. IGI Laboratories, Inc. (NYSEMKT:IG) insider ownership is 0.70%.